The forecast for antiarrhythmic medicine sales in Denmark shows a steady decline from 0.19 USD per capita in 2024 to 0.12 USD per capita in 2028. This represents a year-on-year decrease of approximately 10.5% from 2024 to 2025, around 11.8% from 2025 to 2026, around 6.7% from 2026 to 2027, and about 14.3% from 2027 to 2028. Over the five-year period from 2024 to 2028, the compound annual growth rate (CAGR) is approximately -9.1%.

Future trends to watch for:

The potential development of more advanced antiarrhythmic treatments or alternative therapies that could influence sales.
Healthcare policy changes in Denmark that may impact funding and accessibility to these medications.
Shifts in population health dynamics, such as aging populations or changes in the prevalence of arrhythmias, which could affect demand.